Anne-Marie Carbonell, MD

Anne-Marie Carbonell, MD is Co-Founder and the Chief Executive Officer of OncoSynergy. Dr. Carbonell leads the FDA Investigational New Drug approval of OS2966, a first-in-class anti-CD29 (Beta 1 integrin) monoclonal antibody, from pre-clinical stage to phase 1 clinical trials in recurrent glioblastoma 2H 2020.

Prior to OncoSynergy, Dr. Carbonell played a critical role in the FDA approval of two intracranial stents for the treatment of brain aneurysms at MicroVention/Terumo, and also helped launch a novel minimally invasive spine endoscopy product portfolio at KARL STORZ.

Trained in neurosurgery at the Cleveland Clinic, Dr. Carbonell is the principal investigator of two active NIH grants and is a founding member of the Society of Neuro-oncology Committee for Women & Diversity.